Abstract
Inflammatory bowel diseases (IBD) are chronic, relapsing, and destructive inflammatory disorders of the gastrointestinal tract. Both Crohn’s disease (CD) and ulcerative colitis (UC) seem to arise from an impaired dialog between the environment and gut microbiota in genetically susceptible hosts, leading to an inappropriate immune activation and resulting in the over-production of pro-inflammatory cytokines.
IL-6 is a key modulator of inflammatory response. It is a phylogenetically important cytokine with relevance in IBD, as well as in other chronic inflammatory diseases and cancer. Influencing the production of this cytokine can change the balance of effector CD4+ T cell subsets and induce B cell antibody production. Moreover, given IL-6 is mostly produced from innate immune cells such as macrophages, neutrophils and mast cells, it is a strategic bridge between the innate and the adaptive system. Interestingly, IL-6 induced signaling can be primarily seen in a relatively small number of IL-6 responsive cells whereas in a chronic phase of inflammation it is able to activate almost all cells of the body through a process known as trans-signaling.
In this review, we discuss the role of IL-6 in chronic inflammation, with particular emphasis on its role in CD and UC, and we explore the potential to develop anti-IL-6 agents for IBD treatment.
Keywords: Biologic therapy, cytokine, Crohn’s disease, monoclonal antibody, pathogenesis, ulcerative colitis.
Current Drug Targets
Title:Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target
Volume: 14 Issue: 12
Author(s): Mariangela Allocca, Manol Jovani, Gionata Fiorino, Stefan Schreiber and Silvio Danese
Affiliation:
Keywords: Biologic therapy, cytokine, Crohn’s disease, monoclonal antibody, pathogenesis, ulcerative colitis.
Abstract: Inflammatory bowel diseases (IBD) are chronic, relapsing, and destructive inflammatory disorders of the gastrointestinal tract. Both Crohn’s disease (CD) and ulcerative colitis (UC) seem to arise from an impaired dialog between the environment and gut microbiota in genetically susceptible hosts, leading to an inappropriate immune activation and resulting in the over-production of pro-inflammatory cytokines.
IL-6 is a key modulator of inflammatory response. It is a phylogenetically important cytokine with relevance in IBD, as well as in other chronic inflammatory diseases and cancer. Influencing the production of this cytokine can change the balance of effector CD4+ T cell subsets and induce B cell antibody production. Moreover, given IL-6 is mostly produced from innate immune cells such as macrophages, neutrophils and mast cells, it is a strategic bridge between the innate and the adaptive system. Interestingly, IL-6 induced signaling can be primarily seen in a relatively small number of IL-6 responsive cells whereas in a chronic phase of inflammation it is able to activate almost all cells of the body through a process known as trans-signaling.
In this review, we discuss the role of IL-6 in chronic inflammation, with particular emphasis on its role in CD and UC, and we explore the potential to develop anti-IL-6 agents for IBD treatment.
Export Options
About this article
Cite this article as:
Allocca Mariangela, Jovani Manol, Fiorino Gionata, Schreiber Stefan and Danese Silvio, Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113146660224
DOI https://dx.doi.org/10.2174/13894501113146660224 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Cell-penetrating Peptide-mediated Nanovaccine Delivery
Current Drug Targets Allergic Bronchopulmonary Aspergillosis: AllA Radiologist Needs To Know
Current Pediatric Reviews BCG Vaccine, A Ray of Hope in Treating Severe Acute Respiratory Syndrome (SARS)
Infectious Disorders - Drug Targets Recent Developments in Antiplatelet Therapy after Percutaneus Coronary Intervention
Cardiovascular & Hematological Disorders-Drug Targets Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives
Current Drug Therapy Editorial Statins: [Hot Topic: Statins: Effects Beyond Cholesterol Lowering (Guest Editor: Garry X. Shen)]
Current Drug Targets - Cardiovascular & Hematological Disorders P2RY12 Increased Neuroinflammation to Accelerate Depression-like Behaviors by the NLPR3 Inflammasome
Current Neurovascular Research Synthetic Sphingosine 1-Phosphate Receptor Modulators - Opportunities and Potential Pitfalls
Current Topics in Medicinal Chemistry Adult Neurogenic and Antidepressant Effects of Adiponectin: A Potential Replacement for Exercise
CNS & Neurological Disorders - Drug Targets Proteases and their Receptors as Mediators of Inflammation-Associated Colon Cancer
Current Pharmaceutical Design The Adenosine A2b Receptor: Its Role in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Conformational Flexibility in Designing Peptides for Immunology: The Molecular Dynamics Approach
Current Computer-Aided Drug Design Rational and Random Strategies for the Mimicry of Discontinuous Protein Binding Sites
Protein & Peptide Letters Bone: A Fertile Soil for Cancer Metastasis
Current Drug Targets The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Recent Advances of Small Molecular Regulators Targeting G Protein- Coupled Receptors Family for Oncology Immunotherapy
Current Topics in Medicinal Chemistry The Intracellular Domain of Amyloid Precursor Protein is a Potential Therapeutic Target in Alzheimer’s Disease
Current Drug Discovery Technologies Pregnancy Complicated by the Most Frequent Forms of Maturity Onset Diabetes of the Young: A Narrative Review on Its Pharmacological Implications
Current Reviews in Clinical and Experimental Pharmacology Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha on Dopamine Systems
CNS & Neurological Disorders - Drug Targets